About Leukocyte immunoglobulin-like receptor subfamily A member 5
Leukocyte immunoglobulin-like receptor subfamily A member 5 (LILRA5) is a protein
from Homo sapiens identified by UniProt accession
A6NI73, 299 residues long.
MolForge cross-references it against 0 known binders and
104 disease associations.
Target properties
| Protein name | Leukocyte immunoglobulin-like receptor subfamily A member 5 |
| UniProt accession | A6NI73 |
| Gene | LILRA5 |
| Organism | Homo sapiens |
| Length | 299 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (104)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.44
- high density lipoprotein cholesterol measurement · score 0.31
- blood protein measurement · score 0.31
- late-onset Alzheimers disease · score 0.22
- apolipoprotein A 1 measurement · score 0.21
- Alzheimer disease · score 0.21
- red blood cell density measurement · score 0.12
- stem Cell Factor measurement · score 0.11
- alcohol drinking · score 0.11
- alcohol consumption measurement · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-A6NI73-F1 | alphafold | PREDICTED | 80.22 | — |
Amino-acid sequence (299 residues)
MAPWSHPSAQ LQPVGGDAVS PALMVLLCLG LSLGPRTHVQ AGNLSKATLW AEPGSVISRG NSVTIRCQGT LEAQEYRLVK EGSPEPWDTQ NPLEPKNKAR FSIPSMTEHH AGRYRCYYYS PAGWSEPSDP LELVVTGFYN KPTLSALPSP VVTSGENVTL QCGSRLRFDR FILTEEGDHK LSWTLDSQLT PSGQFQALFP VGPVTPSHRW MLRCYGSRRH ILQVWSEPSD LLEIPVSGAA DNLSPSQNKS DSGTASHLQD YAVENLIRMG MAGLILVVLG ILIFQDWHSQ RSPQAAAGR
Explore Leukocyte immunoglobulin-like receptor subfamily A member 5 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets